Head to Head Survey: Edgewise Therapeutics (NASDAQ:EWTX) and Sarepta Therapeutics (NASDAQ:SRPT)

Edgewise Therapeutics (NASDAQ:EWTX) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Volatility and Risk

Edgewise Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.

Profitability

This table compares Edgewise Therapeutics and Sarepta Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-30.88%	-29.42%
Sarepta Therapeutics	-11.25%	-4.85%	-1.78%

Earnings and Valuation

This table compares Edgewise Therapeutics and Sarepta Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$133.81 million	($1.58)	-19.15
Sarepta Therapeutics	$1.90 billion	1.01	$235.24 million	($3.01)	-6.08

Sarepta Therapeutics has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

86.7% of Sarepta Therapeutics shares are held by institutional investors. 23.2% of Edgewise Therapeutics shares are held by company insiders. Comparatively, 7.6% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Edgewise Therapeutics and Sarepta Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1	2	6	1	2.70
Sarepta Therapeutics	6	13	9	0	2.11

Edgewise Therapeutics currently has a consensus price target of $36.67, indicating a potential upside of 21.21%. Sarepta Therapeutics has a consensus price target of $33.84, indicating a potential upside of 84.82%. Given Sarepta Therapeutics’ higher probable upside, analysts plainly believe Sarepta Therapeutics is more favorable than Edgewise Therapeutics.

Summary

Sarepta Therapeutics beats Edgewise Therapeutics on 9 of the 14 factors compared between the two stocks.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.